Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) traded up 3.8% on Tuesday . The company traded as high as $12.81 and last traded at $12.78. 653,044 shares traded hands during trading, a decline of 51% from the average session volume of 1,332,165 shares. The stock had previously closed at $12.31.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the company. Scotiabank assumed coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective on the stock. Baird R W upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Raymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research note on Thursday, December 12th. Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Piper Sandler cut their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $47.46.
Get Our Latest Analysis on DYN
Dyne Therapeutics Trading Down 1.5 %
The stock has a 50 day moving average price of $13.60 and a two-hundred day moving average price of $24.26. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -3.39 and a beta of 1.11.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, equities analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is owned by company insiders.
Hedge Funds Weigh In On Dyne Therapeutics
A number of large investors have recently added to or reduced their stakes in DYN. Victory Capital Management Inc. increased its holdings in Dyne Therapeutics by 59.4% during the 3rd quarter. Victory Capital Management Inc. now owns 30,537 shares of the company's stock worth $1,097,000 after purchasing an additional 11,385 shares in the last quarter. KBC Group NV increased its holdings in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company's stock worth $77,000 after purchasing an additional 751 shares in the last quarter. Quest Partners LLC increased its holdings in Dyne Therapeutics by 898.3% during the 3rd quarter. Quest Partners LLC now owns 3,434 shares of the company's stock worth $123,000 after purchasing an additional 3,090 shares in the last quarter. Jennison Associates LLC increased its holdings in Dyne Therapeutics by 1.5% during the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company's stock worth $48,383,000 after purchasing an additional 19,730 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Dyne Therapeutics during the 3rd quarter worth about $1,478,000. Institutional investors own 96.68% of the company's stock.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Read More
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
